Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 27.5% from a year ago

Cash & equivalents stood at $82.73M at the end of Q3 FY2026, up 27.5% from a year earlier and down 48.9% from the prior quarter. Over 3 fiscal years it compounded at +35.0% a year.

Context

  • Cash & equivalents amounted to 7.5% of total assets at the end of Q3 FY2026, down 5.3 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +27.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$82.73M-48.9% QoQ
Last fiscal yearDec 2025
$85.72M-4.1% YoY
Year agoSep 2025
$64.9M+27.5% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.5%——
1 year-4.1%——
3-year CAGR+35.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
85.72M USD
Year-over-year change
-4.1%
4-year CAGR
+54.3%

Cash & Equivalents vs competitors

How SYRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +27.5% is the 5th highest of 8, against a peer median of +35.6%.
  • Cash & equivalents amounts to 7.5% of total assets for SYRE, versus a peer median of 53.0%.
SYRE Competitors
Cash & Equivalents for SYRE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABVXAbivax S.A.Jun 2026€387.99M EUR+536.6%+167.6%83.9%
ANABAnaptysBio, Inc.Mar 2026$248.47M USD+151.9%+49.5%75.4%
IMUXImmunic, Inc.Mar 2026$186.63M USD+1204.7%-47.5%98.4%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€129.59M EUR——78.2%
UPBUpstream Bio, Inc.Mar 2026$96.72M USD+35.6%+81.3%30.4%
SYRESpyre Therapeutics, Inc.Sep 2026$82.73M USD+27.5%+35.0%7.5%
ARDXArdelyx, Inc.Mar 2026$31.21M USD+1.3%-10.9%6.2%
ACRSAclaris Therapeutics, Inc.Mar 2026$28.66M USD-5.6%-23.9%14.4%
IFRXInflaRx N.V.Mar 2026€15.01M EUR-68.3%-0.5%30.7%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding SYRE) —+35.6%-0.5%53.0%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents15.14M34.86M188.89M89.42M85.72M
Short-term Investments77.99M20.85M150.38M513.67M670.81M
Net Receivables815K375K000
Inventory00000
Other Current Assets06.17M2.25M5.39M21.25M
Total Current Assets98.89M62.26M341.53M608.47M777.78M
Property, Plant & Equipment (Net)8.36M6.65M000
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2.68M2.24M331K10K0
Total Non-current Assets11.04M8.89M331K10K0
Total Assets109.93M71.14M341.86M608.48M777.78M
Account Payables3.32M677K896K666K8.9M
Short-term Debt00000
Tax Payables00000
Deferred Revenue2.36M517K000
Other Current Liabilities4.99M4.92M5.93M31.27M30.94M
Total Current Liabilities20.14M14.66M31.98M54.06M58.69M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)1.22M2.18M000
Other Non-current Liabilities00125.87M36.62M3.86M
Total Non-current Liabilities5.84M6.18M125.87M36.62M3.86M
Total Liabilities25.99M20.84M157.84M90.68M62.55M
Common Stock5K6K10K13K15K
Retained Earnings(341.81M)(425.62M)(764.41M)(972.43M)(1.13B)
Accumulated OCI(20K)(48K)302K180K869K
Other Stockholders Equity00000
Minority Interest00000
Total Equity83.94M50.31M184.02M517.8M715.24M
Total Debt5.06M4.63M000
Net Debt(10.08M)(30.23M)(188.89M)(89.42M)(85.72M)

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.